Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 30, 2015 4:15 AM ET


Company Overview of Theraclone Sciences, Inc.

Company Overview

Theraclone Sciences, Inc., a discovery-stage biotech company, develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. It provides In-Situ Therapeutic Antibody Rescue technology, which allows for the rapid testing of human antibodies to find those with exceptional biological functions and activities; and TCN-032, a recombinant human monoclonal antibody for the treatment of patients hospitalized with serious influenza. The company has antibody programs at preclinical and clinical development stage targeting serious medical conditions with a significant unmet medical need, including triple negative and endocrine treatment resistant HER-2 negative breast cancer...

1124 Columbia Street

Seattle Life Sciences Building

Suite 300

Seattle, WA 98104

United States

Founded in 2004





Key Executives for Theraclone Sciences, Inc.

Chief Executive Officer and Director
Age: 56
Founder and Member of Scientific Advisory Board
Chief Financial Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Theraclone Sciences, Inc. Key Developments

Wellcome Trust Selects Theraclone Sciences, Inc.'s I-STAR™ Technology to Identify Therapeutic Antibodies Against Ebola Virus

Theraclone Sciences, Inc. announced that its I-STAR™ Technology chosen by Wellcome Trust to identify Therapeutic Antibodies against Ebola Virus. The company will identify potential therapeutic antibodies against the Ebola virus utilizing the Company’s powerful human memory B-cell interrogation platform. The I-STARTM technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BIO Ventures for Global Health was instrumental in forming a consortium of Ebola experts for the endeavor, and will collaborate with Theraclone on management of the project. To fund the initial screening and development efforts, Theraclone will receive up to $4.4 million in a Series C financing, which includes an investment from the Wellcome Trust along with existing investors.

Theraclone Sciences, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:20 AM

Theraclone Sciences, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:20 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Theraclone Sciences, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015

Theraclone Sciences, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 through Feb-10-2015. Venue: The Waldorf Astoria, New York, New York, United States. Presentation Date & Speakers: Feb-10-2015, Clifford J. Stocks, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Berkeley Bioengineering Co. United States
Percivia LLC United States
TGG Medical Transitory, Inc. United States
Agilis Biotherapeutics, LLC United States
Immunomic Therapeutics, Inc. United States

Recent Private Companies Transactions

Private Placement
April 24, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Theraclone Sciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at